Circulating microparticles and activated platelets as novel prognostic biomarkers in COVID-19; relation to cancer.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
28
08
2020
accepted:
26
01
2021
entrez:
22
2
2021
pubmed:
23
2
2021
medline:
3
3
2021
Statut:
epublish
Résumé
The study aimed to determine whether the MPs levels and platelet activation are affected by the COVID-19 infection in both malignant and non-malignant patients compared to healthy individuals and define their contribution to the COVID-19 associated coagulopathy and the relation of these MPs to other hematologic parameters. We recruited 23 malignant patients with reverse transcription polymerase chain reaction (RT-PCR) positive COVID-19, also, 19 COVID-19 non-malignant patients, and 20 healthy volunteers were also enrolled for comparison. Blood samples were collected from patients and healthy donors into 5 mL vacutainer tube containing 3.5% buffered sodium citrate solution for measurement of total microparticles (TMPs), platelet microparticles (PMPs), endothelial microparticles (EMPs), CD62 activated platelets, and CD41 platelet marker. COVID-19 malignant patients had significantly lower hemoglobin and platelets compared to COVID non-malignant ones, while they had significantly higher C-reactive protein, LDH, AST, Albunim, creatinine, and prognostic index (PI) compared to COVID-19 non-malignant patients. significant accumulations of TMPs, PMPs, EMPs, and activated platelets in COVID-19 affected patients compared to healthy controls. TMPs, and EMPs were significantly accumulated in COVID-19 malignant compared to COVID-19 non-malignant patients with no significant difference in PMPs between both. Circulating MPs and activated platelets may be promising novel prognostic biomarkers capable of identifying potentially severe COVID-19 patients who require immediate care especially in cancer patients.
Sections du résumé
BACKGROUND AND AIM
The study aimed to determine whether the MPs levels and platelet activation are affected by the COVID-19 infection in both malignant and non-malignant patients compared to healthy individuals and define their contribution to the COVID-19 associated coagulopathy and the relation of these MPs to other hematologic parameters.
PATIENTS AND METHODS
We recruited 23 malignant patients with reverse transcription polymerase chain reaction (RT-PCR) positive COVID-19, also, 19 COVID-19 non-malignant patients, and 20 healthy volunteers were also enrolled for comparison. Blood samples were collected from patients and healthy donors into 5 mL vacutainer tube containing 3.5% buffered sodium citrate solution for measurement of total microparticles (TMPs), platelet microparticles (PMPs), endothelial microparticles (EMPs), CD62 activated platelets, and CD41 platelet marker.
RESULTS
COVID-19 malignant patients had significantly lower hemoglobin and platelets compared to COVID non-malignant ones, while they had significantly higher C-reactive protein, LDH, AST, Albunim, creatinine, and prognostic index (PI) compared to COVID-19 non-malignant patients. significant accumulations of TMPs, PMPs, EMPs, and activated platelets in COVID-19 affected patients compared to healthy controls. TMPs, and EMPs were significantly accumulated in COVID-19 malignant compared to COVID-19 non-malignant patients with no significant difference in PMPs between both.
CONCLUSION
Circulating MPs and activated platelets may be promising novel prognostic biomarkers capable of identifying potentially severe COVID-19 patients who require immediate care especially in cancer patients.
Identifiants
pubmed: 33617530
doi: 10.1371/journal.pone.0246806
pii: PONE-D-20-27029
pmc: PMC7899358
doi:
Substances chimiques
Biomarkers
0
Hemoglobins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0246806Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Transfusion. 2006 Jul;46(7):1199-209
pubmed: 16836568
Oncotarget. 2018 Jun 29;9(50):29351-29364
pubmed: 30034622
J Clin Invest. 2012 Jul;122(7):2331-6
pubmed: 22751108
Blood Rev. 2007 May;21(3):157-71
pubmed: 17118501
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Radiology. 2020 Jun;295(3):200463
pubmed: 32077789
PLoS One. 2020 Mar 19;15(3):e0230548
pubmed: 32191764
Clin Chem. 2005 Dec;51(12):2333-40
pubmed: 16195357
PLoS One. 2013 Jul 29;8(7):e69034
pubmed: 23922679
J Gastrointestin Liver Dis. 2008 Sep;17(3):261-8
pubmed: 18836617
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Scand J Immunol. 2007 Aug-Sep;66(2-3):159-65
pubmed: 17635793
Thromb Res. 2012 Apr;129 Suppl 1:S132-6
pubmed: 22682124
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2003 Nov;1(11):2434-43
pubmed: 14629480
JAMA. 2020 Apr 7;323(13):1243-1244
pubmed: 32077901
Int J Cancer. 2005 Feb 20;113(5):752-60
pubmed: 15499615
Blood. 2020 Jun 4;135(23):2033-2040
pubmed: 32339221
J Intensive Care. 2015 Jan 07;3(1):2
pubmed: 25705427
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Eur Radiol. 2020 Aug;30(8):4381-4389
pubmed: 32193638
Sci Rep. 2015 Dec 04;5:17611
pubmed: 26635081
Biomed Res Int. 2014;2014:173401
pubmed: 25061601
Crit Rev Oncol Hematol. 1999 Apr;30(2):111-42
pubmed: 10439058
Oncotarget. 2017 Jun 6;8(44):75952-75967
pubmed: 29100283
Am J Hematol. 2020 Aug;95(8):999-1000
pubmed: 32212392
Clin Cancer Res. 2009 Nov 15;15(22):6830-40
pubmed: 19861441
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
AJR Am J Roentgenol. 2020 Jul;215(1):87-93
pubmed: 32174129
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Int J Lab Hematol. 2013 Jun;35(3):254-61
pubmed: 23590652
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Thromb Haemost. 2015 Aug 31;114(3):449-58
pubmed: 26293514